Suprachoroidal triamcinolone for macular edema from non-infectious uveitis after failed sub-Tenon injections
Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
We will test whether a single suprachoroidal triamcinolone injection can improve vision and reduce central retinal swelling in people with macular edema from non-infectious uveitis who did not improve after sub-Tenon steroid injections.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Baghdad Academic / other |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT07145008 on ClinicalTrials.gov |
What this trial studies
Participants receive a baseline eye exam including vision testing, slit-lamp exam, and OCT retinal imaging. They then receive one suprachoroidal triamcinolone injection under topical anesthetic in a sterile operating-room setting with standard monitoring. Follow-up visits occur about 1 month and 3 months after treatment with repeat vision tests and OCT scans to measure change in visual acuity and retinal thickness. Participants are instructed to contact the clinic for new pain, redness, floaters, or worsening vision.
Who should consider this trial
Good fit: Adults (18+) with non-infectious uveitis causing macular edema of less than four months' duration that persisted despite posterior sub-Tenon triamcinolone are ideal candidates.
Not a fit: Patients with epiretinal membrane–associated macular edema, infectious uveitis, children under 18, or chronic macular edema beyond the specified duration are unlikely to benefit or are excluded.
Why it matters
Potential benefit: If successful, the procedure could improve vision and reduce central retinal swelling in patients whose uveitic macular edema did not respond to sub-Tenon steroid injections.
How similar studies have performed: Suprachoroidal delivery of triamcinolone and similar approaches have shown promising results in prior clinical work for uveitic macular edema, so this builds on emerging evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-infectious uveitis complicated with macular edema * Uveitic macular edema of less than four months' duration * Macular edema persisted despite lack of intra-ocular inflammation * No response to posterior sub-Tenon triamcinolone acetonide injections Exclusion Criteria: * Those with epiretinal membrane-associated macular edema * Below 18 years
Where this trial is running
Baghdad
- Ibn Al-Haitham Eye Teaching Hospital — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: Mohammed Suhail Al-Salam
- Email: mohammedsuhail@uomustansiriyah.edu.iq
- Phone: +964 790 183 6367
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.